Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,750.5 | 96.17 | 4,19,727.66 | 705.44 | 0.91 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,316 | 65.01 | 1,67,235.91 | 598 | 0.48 | 2,578 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,341 | 65.8 | 1,46,951.32 | 577 | 0.14 | 2,547 | 249.82 |
Dr Reddys Laboratories Ltd DRREDDY | 1,291.2 | 23.23 | 1,07,764.93 | 90.6 | 0.62 | 4,266.4 | 377.55 |
Cipla Ltd CIPLA | 1,313.2 | 23.14 | 1,06,033.33 | 616.88 | 1.22 | 4,256.93 | 411.55 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
